Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma Plc LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 46.00 44.00 48.00 46.00 46.00 46.00 7,826 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -24.1 -18.9 - 49

Verona Pharma plc Verona Pharma Plc To Announce Financial Results For Full Year Ended December 31, 2019 And Provide Corporate...

21/02/2020 7:00am

UK Regulatory (RNS & others)


 
TIDMVRP 
 
   LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on respiratory diseases,  announces that it will report 
its audited financial results for the full year ended December 31, 2019 
on Thursday, February 27, 2020 and host an investment community 
conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss the full 
year financial results and provide a corporate update. 
 
   To participate, please dial one of the following numbers and reference 
conference ID 5394158: 
 
 
   -- 866-940-4574 for callers in the United States 
 
   -- 0800 028 8438 for callers in the United Kingdom 
 
   -- 0800 181 5287 for callers in Germany 
 
 
   A live webcast will be available on the Events and presentations link on 
the Investors page of the Company's website, 
https://www.globenewswire.com/Tracker?data=vzKXAOPJ7ycL4BPsNYPTJXrJoe5EwvCbtnJH9McgATjS45NhcW9XWPK7TG1H4DTbdnNXIBFF8x201OkOU-orgBubVHy46_bWOoryAuRacl0= 
www.veronapharma.com, and an audio replay will be available there for 30 
days. 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. Verona Pharma is currently 
in Phase 2 development with three formulations of ensifentrine for the 
treatment of COPD: nebulized, dry powder inhaler, and pressurized 
metered-dose inhaler. Ensifentrine also has potential applications in 
cystic fibrosis, asthma and other respiratory diseases. For more 
information, please visit 
https://www.globenewswire.com/Tracker?data=vzKXAOPJ7ycL4BPsNYPTJXjleuH4-XOMeUMkObg_VtsbZGIKeWCOdEAZam8e13JPfw7CLiteMNAXruNJ-lhJG2RQsewWzObkDopYIPfjejg= 
www.veronapharma.com. 
 
 
 
 
 
  Verona Pharma plc                                          Tel: +44 (0)20 3283 4200 
---------------------------------------------------------  --------------------------- 
  David Zaccardelli, Chief Executive Officer                 info@veronapharma.com 
---------------------------------------------------------  --------------------------- 
  David Moskowitz, VP Capital Markets Strategy & Investor 
   Relations (Investor Enquiries) 
   Victoria Stewart, Director of Communications (Media 
   Enquiries) 
---------------------------------------------------------  --------------------------- 
 
  N+1 Singer                                                 Tel: +44 (0)20 3283 4200 
   (Nominated Adviser and UK Broker) 
---------------------------------------------------------  --------------------------- 
  Aubrey Powell / George Tzimas / Iqra Amin (Corporate 
   Finance) 
---------------------------------------------------------  --------------------------- 
  Tom Salvesen (Corporate Broking) 
---------------------------------------------------------  --------------------------- 
 
  Optimum Strategic Communications                           Tel: +44 (0)20 950 9144 
   (European Media and Investor Enquiries)                    verona@optimumcomms.com 
---------------------------------------------------------  --------------------------- 
  Mary Clark / Eva Haas / Hollie Vile 
---------------------------------------------------------  --------------------------- 
 
  Argot Partners                                             Tel: +1 212-600-1902 
   (US Investor Enquiries)                                    verona@argotpartners.com 
---------------------------------------------------------  --------------------------- 
  Stephanie Marks / Kimberly Minarovich / Michael Barron 
---------------------------------------------------------  --------------------------- 
 
 
 
 
 
 

(END) Dow Jones Newswires

February 21, 2020 02:00 ET (07:00 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Verona Pharma Chart

1 Year Verona Pharma Chart

1 Month Verona Pharma Chart

1 Month Verona Pharma Chart
ADVFN Advertorial
Your Recent History
LSE
VRP
Verona Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200605 19:46:07